Carr Brittany J, Nguyen Cynthia T, Stell William K
Department of Neuroscience, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada.
O'Brien Centre for the Bachelor of Health Sciences, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada.
Clin Exp Optom. 2019 Jul;102(4):418-425. doi: 10.1111/cxo.12871. Epub 2019 Jan 30.
The putative myopia-controlling receptor is thought to be muscarinic acetylcholine receptor subtype M , because mamba toxin-3 can inhibit form-deprivation myopia in chicks at a far lower concentration than atropine. However, mamba toxin-3 is equally potent at the human α -, α -, and α -adrenoceptors. To test the hypothesis that α-adrenoceptors might be involved in regulation of eye growth, the treatment effects of α -adrenoceptor agonists brimonidine, clonidine, and guanfacine, and antagonist yohimbine, on form-deprivation myopia in the chick were measured.
Right eyes of White Leghorn chicks were goggled with diffusers to induce form-deprivation myopia; left eyes were left open as controls. Goggled eyes were injected intravitreally with 20 μL of vehicle, or 2, 20, or 200 nmol of brimonidine, clonidine, guanfacine, or yohimbine, 24, 72, and 120 hours after goggle application. Alternatively, myopia was inhibited physiologically by goggle removal for two hours, and the α -adrenoceptor antagonist, yohimbine, was injected to test whether it could block this type of myopia inhibition. One day after the last injection, refractive error and axial length were measured.
Brimonidine (20 and 200 nmol) and clonidine (200 nmol) effectively inhibited experimentally induced increases in negative refractive error and axial elongation. All doses of guanfacine significantly inhibited induced negative refractive error, but only 20 and 200 nmol significantly inhibited axial elongation. Yohimbine had no effect on form-deprivation myopia, but 200 nmol reduced the myopia-inhibiting effect of goggle removal.
High concentrations of α -adrenoceptor agonists, similar to those required by atropine, inhibited chick form-deprivation myopia; antagonism by yohimbine had no effect. High-concentration yohimbine partially interfered with emmetropisation in form-deprived chicks experiencing normal vision for two hours per day. These data support the hypothesis that treatment with high concentrations of adrenergic drugs can affect experimentally induced myopia and normal visual processes.
假定的近视控制受体被认为是毒蕈碱型乙酰胆碱受体M亚型,因为曼巴蛇毒素-3能以远低于阿托品的浓度抑制雏鸡的形觉剥夺性近视。然而,曼巴蛇毒素-3对人α1、α2和α3肾上腺素能受体的作用强度相同。为了验证α肾上腺素能受体可能参与眼生长调节这一假说,测定了α肾上腺素能受体激动剂溴莫尼定、可乐定和胍法辛以及拮抗剂育亨宾对雏鸡形觉剥夺性近视的治疗效果。
给白来航雏鸡的右眼戴上扩散器以诱导形觉剥夺性近视;左眼不做处理作为对照。在戴上扩散器24、72和120小时后,给戴扩散器的眼睛玻璃体内注射20μL赋形剂,或2、20或200nmol的溴莫尼定、可乐定、胍法辛或育亨宾。或者,通过摘除扩散器两小时生理性抑制近视,并注射α肾上腺素能受体拮抗剂育亨宾,以测试其是否能阻断这种类型的近视抑制。最后一次注射后一天,测量屈光不正和眼轴长度。
溴莫尼定(20和200nmol)和可乐定(200nmol)有效抑制了实验诱导的负性屈光不正增加和眼轴伸长。所有剂量的胍法辛均显著抑制诱导的负性屈光不正,但只有20和200nmol显著抑制眼轴伸长。育亨宾对形觉剥夺性近视无作用,但200nmol降低了摘除扩散器的近视抑制效果。
高浓度的α肾上腺素能受体激动剂,与阿托品所需浓度相似,可抑制雏鸡形觉剥夺性近视;育亨宾拮抗无效。高浓度育亨宾部分干扰了每天有两小时正常视力的形觉剥夺雏鸡的正视化过程。这些数据支持了高浓度肾上腺素能药物治疗可影响实验诱导的近视和正常视觉过程这一假说。